Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK10 | P53779 | 6/20 | 0.51 |
| ▸ | JUN | P05412 | 5/20 | 0.51 |
| ▸ | MAPK8 | P45983 | 4/20 | 0.51 |
| ▸ | EGFR | P00533 | 1/20 | 0.51 |
| ▸ | TNK2 | Q07912 | 2/20 | 0.49 |
| ▸ | CNR2 | P34972 | 5/20 | 0.49 |
| ▸ | JAK2 | O60674 | 2/20 | 0.49 |
| ▸ | BRD4 | O60885 | 2/20 | 0.49 |
| ▸ | PAK1 | Q13153 | 2/20 | 0.47 |
| ▸ | CTSC | P53634 | 1/20 | 0.47 |
| ▸ | JAK3 | P52333 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1633250 | 0.91 | AXL (0.52) | MAPK10JUNMAPK8EGFRCNR2 | |
| SCHEMBL1632167 | 0.90 | MAPK10 (0.57) | MAPK10JUNMAPK8EGFRCNR2 | |
| SCHEMBL18377031 | 0.87 | JAK2 (0.55) | MAPK10JUNMAPK8EGFRJAK2 | |
| SCHEMBL1633145 | 0.84 | MAPK10 (0.55) | MAPK10JUNMAPK8EGFRJAK2 | |
| SCHEMBL1633898 | 0.82 | BRD4 (0.56) | MAPK10JUNMAPK8EGFRJAK2 | |
| SCHEMBL1633048 | 0.81 | MAPK10 (0.66) | MAPK10JUNMAPK8EGFRJAK2 | |
| SCHEMBL29370855 | 0.79 | TTK (0.61) | MAPK10JUNMAPK8EGFRJAK2 | |
| SCHEMBL16514444 | 0.79 | CNR2 (0.56) | MAPK10JUNMAPK8CNR2JAK2 | |
| SCHEMBL18376727 | 0.79 | TTK (0.61) | MAPK10JUNMAPK8EGFRJAK2 | |
| SCHEMBL1634529 | 0.79 | EGFR (0.56) | MAPK10JUNEGFRJAK2BRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7932262-B2 | Quinazolines for PDK1 inhibition | NOVARTIS AG (CH) | 2011-04-26 | — | — | US | disclosed |
| US-7932262-B2 | Quinazolines for PDK1 inhibition | NOVARTIS AG (CH) | 2011-04-26 | — | — | US | disclosed |
| US-20100048561-A1 | QUINAZOLINES FOR PDK1 INHIBITION | NOVARTIS VACCINES & DIAGNOSTICS, INC. (US) | 2010-02-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048561-A1 | QUINAZOLINES FOR PDK1 INHIBITION | PDK1, PDK2, PDK3 | MAPK10 402/4885JUN 544/4885MAPK8 267/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.